TG Therapeutics Inc TGTX

Healthcare Biotechnology

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

NDAQ:TGTX - Post by User

TG Therapeutics Inc

<< Previous

Bullboard Posts

Post by stockpsychoon May 10, 2023 12:02am

170 Views

Post# 35439976

therapeutic gift

Check out this amazing investment opportunity: I just bought shares of XYZ company at $10, and sold a call option with a strike price of $12 for $1. If the stock price stays below $12 until the option expires, I keep the $1 premium. If the stock price rises above $12, I'm obligated to sell my shares for $12, but I still get to keep the $1 premium. It's a win-win situation! Happy investing!

<< Previous

Bullboard Posts

One of the strongest contenders to lead Canada’s cannabis market